Therapeutic regimen of metastatic hormone sensitive prostate cancer: a case report and literature review
10.3760/cma.j.cn112330-20210408-00006
- VernacularTitle:转移性激素敏感性前列腺癌一例报告并文献复习
- Author:
Hao LIU
1
;
Jibiao LI
Author Information
1. 中山大学孙逸仙纪念医院泌尿外科，广州 510120
- Keywords:
Prostatic neoplasms;
Metastatic;
Hormone sensitivity;
Androgen deprivation therapy;
Abiraterone
- From:
Chinese Journal of Urology
2021;42(Z1):24-26
- CountryChina
- Language:Chinese
-
Abstract:
Many clinical trials have shown that androgen deprivation therapy (ADT) combined with novel hormonal therapy or chemotherapy can improve the overall outcome of metastatic hormone-sensitive prostate cancer (mHSPC) patients. In this article, we report a patient with mHSPC diagnosed as stage T 3bN 0M 1b, who had a significant PSA decrease after receiving ADT combined with abiraterone acetate and underwent corticosteroid switch due to adverse events. This case suggest that ADT combined with abiraterone acetate could improve the overall survival of mHSPC patients, but clinicians should make individualized treatment plan based on patients special condition.
